首页> 外文期刊>Journal of neuro-oncology. >Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.
【24h】

Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.

机译:IL-2和阿霉素的局部递送在实验性恶性神经胶质瘤的治疗中具有协同作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

INTRODUCTION: Local delivery of adriamycin (ADR) via biodegradable polymers has been shown to improve survival in rats challenged intracranially with 9L gliosarcoma. Likewise, local delivery of interleukin-2 (IL-2) has been shown to extend survival in experimental brain tumor models. In the current study, we hypothesized that local delivery of ADR and IL-2 might act synergistically against experimental intracranial glioma. METHODS: Polyanhydride polymers (PCPP-SA) containing 5% ADR by weight were prepared using the mix-melt method. IL-2 polymer microspheres (IL-2 MS) were produced via the complex coacervation of gelatin and chondroitin sulfate in the presence of IL-2. Sixty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. In addition, a group of rats were injected with either IL-2 MS or empty microspheres. Five days later they received ADR or blank polymer. There were a total of four treatment groups: (1) empty microspheres, blank polymer; (2) empty microspheres, ADR polymer; (3) IL-2 MS, blank polymer; and (4) IL-2 MS, ADR polymer. RESULTS: Compared to control animals treated with empty microspheres and blank polymer, animals receiving empty microspheres and ADR polymer (P < 0.0004), IL-2 MS and blank polymer (P < 0.0005), and IL-2 MS combined with ADR polymer (P < 0.0000002) all showed statistically significant improvement in survival. In addition, animals receiving the IL-2/ADR combination had significantly extended survival compared to either ADR or IL-2 alone (P < 0.000003 and P < 0.0004, respectively). CONCLUSIONS: Both ADR and IL-2, when delivered locally, are effective monotherapeutic agents against experimental intracranial gliosarcoma. The combination ADR and IL-2 therapy is more effective than either agent alone.
机译:简介:通过生物可降解聚合物局部递送阿霉素(ADR)可以改善颅内受到9L胶质肉瘤攻击的大鼠的存活率。同样,白介素2(IL-2)的局部递送已显示出可延长实验性脑肿瘤模型的生存期。在当前的研究中,我们假设ADR和IL-2的局部递送可能协同对抗实验性颅内神经胶质瘤。方法:采用混合熔融法制备了ADR含量为5%的聚酸酐聚合物(PCPP-SA)。 IL-2聚合物微球(IL-2 MS)是在IL-2存在下,通过明胶和硫酸软骨素的复合凝聚而产生的。 60只雄性Fisher 344大鼠接受了致命剂量的9L神经胶质肉瘤细胞的颅内攻击。另外,向一组大鼠注射IL-2 MS或空的微球。五天后,他们收到了ADR或空白聚合物。总共有四个治疗组:(1)空的微球,空白聚合物; (2)空的微球,ADR聚合物; (3)IL-2 MS,空白聚合物; (4)IL-2MS,ADR聚合物。结果:与用空微球和空白聚合物治疗的对照动物相比,接受空微球和ADR聚合物(P <0.0004),IL-2 MS和空白聚合物(P <0.0005)和IL-2 MS与ADR聚合物联合治疗的动物(P <0.0004) P <0.0000002)均显示生存率有统计学显着性改善。此外,与单独使用ADR或IL-2相比,接受IL-2 / ADR组合的动物的生存期显着延长(分别为P <0.000003和P <0.0004)。结论:当局部递送时,ADR和IL-2都是有效的抗实验性颅内神经胶质肉瘤的单一治疗药物。 ADR和IL-2的联合治疗比单独使用任何一种药物更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号